Curaleaf Receives All Required Competition Law Clearances for Proposed Acquisition of Aurora Cannabis
Germany and Canada were the only jurisdictions requiring competition clearance; remaining offer conditions still apply.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Curaleaf Holdings (CURLF) has received all required competition law clearances for its proposed acquisition of Aurora Cannabis.
Germany and Canada were the only jurisdictions requiring competition clearance. Germany's economy ministry approved the proposed purchase of 100% of voting rights in three Aurora subsidiaries on October 20, 2026. Canada's Competition Bureau issued a no-action letter on November 2, indicating no intention at that time to challenge the acquisition. Germany's Federal Cartel Office cleared implementation on November 3.
The offer for all outstanding Aurora common shares, enhanced on October 6, remains open until December 4, 2026, unless withdrawn or amended. Completion remains subject to remaining offer conditions being satisfied or waived. Organigram also has a proposed acquisition pending shareholder, court and regulatory approvals.
Positive
- Minor pointAll required competition law clearances secured in Germany and Canada for the proposed Aurora acquisition.
Negative
- Minor pointAcquisition completion remains conditional on remaining offer conditions being satisfied or waived.
- Minor pointOrganigram's competing acquisition proposal remains pending shareholder, court and regulatory approvals.
AI-generated analysis. How Rhea-AI works. Not financial advice.
On October 20, 2026 Germany's Federal Ministry for Economic Affairs and Energy granted approval for the proposed acquisition of
On November 2, 2026,
On November 3, 2026,
Curaleaf's enhanced premium bid of October 6, 2026 to purchase all of the outstanding common shares of Aurora (the "Offer") remains outstanding and is set to expire on December 4, 2026 unless withdrawn or amended.
"With all required competition law clearances secured, the path is clear for Aurora shareholders to realize the value our Offer provides," said Boris Jordan, Chairman of the Board and Chief Executive Officer of Curaleaf. "We appreciate the constructive engagement of the regulators who reviewed the transaction."
Curaleaf's required competition law reviews are complete, while Organigram's proposed acquisition remains subject to shareholder, court, and regulatory approvals. Curaleaf believes these clearances strengthen its Offer by providing greater certainty of completion and supporting a faster path to closing, subject to the Offer's remaining conditions being satisfied or waived. The Company believes Aurora shareholders should consider this advantage when evaluating the competing proposals.
IMPORTANT INFORMATION
This document does not constitute an offer to buy or the solicitation of an offer to sell any securities. The Offer is made solely by the Offer to Purchase and Circular dated August 18, 2026, as amended on October 6, 2026 and as may be further amended or supplemented (the "Offer to Purchase and Circular").
SECURITY HOLDERS ARE URGED TO READ THE OFFER TO PURCHASE AND CIRCULAR, THE REGISTRATION STATEMENT ON FORM F-80, THE TENDER OFFER STATEMENT ON SCHEDULE 14D-1F, AND ALL OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE
NOTICE TO
The enforcement by investors of civil liabilities under the federal securities laws may be affected adversely by the fact that the subject company is located in a foreign country, and that some or all of its officers and directors are residents of a foreign country.
Investors should be aware that the bidder or its affiliates, directly or indirectly, may bid for or make purchases of the issuer's securities subject to the offer or of the issuer's related securities, or of the bidder's securities to be distributed or of the bidder's related securities, during the period of the tender offer, as permitted by applicable Canadian laws or provincial laws or regulations.
Curaleaf has filed with the SEC a Registration Statement on Form F-80 under the
THE OFFER AND THE CURALEAF SUBORDINATE VOTING SHARES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY
The Curaleaf subordinate voting shares issuable under the Offer have not been registered or otherwise qualified for offer and sale in certain
FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws (together, "forward-looking statements"), including statements regarding the Offer, and Curaleaf's intentions with respect to the Offer and Aurora. Forward-looking statements can generally be identified by words such as "will," "intend," "expect," "believe," "may," "could" or similar expressions. Forward-looking statements are based on Curaleaf's current expectations and assumptions and are subject to known and unknown risks, uncertainties and other factors, many of which are beyond Curaleaf's control, that could cause actual results to differ materially, including the response of Aurora and its board of directors to the Offer, the satisfaction or waiver of the conditions of the Offer, and the other risks described in the Offer to Purchase and Circular and in Curaleaf's filings available at www.sedarplus.ca and www.sec.gov. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. Curaleaf undertakes no obligation to update any forward-looking statements, except as required by applicable law.
AURORA AND ORGANIGRAM INFORMATION
Information concerning Aurora and Organigram herein is based solely on Aurora's and Organigram's publicly available filings and other public sources. Neither Aurora nor Organigram has not reviewed this document. Neither Curaleaf nor its officers or directors assume responsibility for the accuracy or completeness of such information.
About Curaleaf
Curaleaf is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, Curaleaf and its brands, including Curaleaf, Select, Grassroots, Find, Dark Heart, and Anthem provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is powered by a strong presence in all stages of the supply chain. Its unique distribution network throughout Europe, Canada and Australasia brings together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf's subordinate voting shares are listed on the Toronto Stock Exchange under the symbol CURA and trade on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.
Investor Contact:
Curaleaf Holdings, Inc.
Camilo Lyon, Chief Investment Officer
IR@curaleaf.com
Media Contact:
MATTIO Communications
MattioCuraleaf@Mattio.com
Shareholder Contact
Carson Proxy Advisors
North American Toll Free Phone: 1-800-530-5189
Local (Collect outside North America): 416-751-2066
Email: info@carsonproxy.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/curaleaf-receives-all-required-competition-law-clearances-for-proposed-acquisition-of-aurora-cannabis-302934337.html
SOURCE Curaleaf Holdings, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Has Curaleaf received all competition approvals for its proposed Aurora acquisition?
Curaleaf has received all required competition law clearances in Germany and Canada, the only jurisdictions requiring them. These clearances do not complete the acquisition: the offer's remaining conditions must still be satisfied or waived.